These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The HLA molecules: function and role in allorecognition. Thorsby E Transplant Proc; 1994 Jun; 26(3):1699-701. PubMed ID: 8030091 [No Abstract] [Full Text] [Related]
7. Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings. Okumura H; Yamaguchi M; Kotani T; Sugimori N; Sugimori C; Ozaki J; Kondo Y; Yamazaki H; Chuhjo T; Takami A; Ueda M; Ohtake S; Nakao S Eur J Haematol; 2007 Feb; 78(2):157-60. PubMed ID: 17313562 [TBL] [Abstract][Full Text] [Related]
8. [Findings and hypotheses in the immunological etiology of gestosis and intrauterine fetal growth retardation]. Hinney B; Nesselhut T Gynakologe; 1990 Jun; 23(3):164-71. PubMed ID: 2201603 [No Abstract] [Full Text] [Related]
9. Effector cells of graft-versus-host disease, host resistance, and the graft-versus-leukemia effect: summary of a workshop on bone marrow transplantation. Ringdén O; Deeg HJ; Beschorner W; Slavin S Transplant Proc; 1987 Feb; 19(1 Pt 3):2758-61. PubMed ID: 3547953 [No Abstract] [Full Text] [Related]
10. [Graft versus host disease: the most threatening complication of bone marrow transplant. Review of the literature]. Rasero L; Bonavita K; Marsullo M Assist Inferm Ric; 2002; 21(4):211-21. PubMed ID: 12674033 [No Abstract] [Full Text] [Related]
11. [Mechanisms and clinical expression of graft rejection and graft-versus-host disease]. Vignes S; Farge D Rev Prat; 1997 Nov; 47(18):2073-9. PubMed ID: 9501628 [No Abstract] [Full Text] [Related]
12. [Acute lymphoblastic and nonlymphoblastic leukemia in 1st complete remission: consolidation treatment by intensive radio-chemotherapy followed by transplantation of HLA-A, B and Dr compatible allogeneic bone marrow]. Gyger M; Perreault C; Bonny Y; Bélanger R; David M; Boileau J; Tawil E; Lavallée R; Lacombe M; d'Angelo G Union Med Can; 1986 Oct; 115(10):699-702. PubMed ID: 3541340 [No Abstract] [Full Text] [Related]
13. Recognition of HLA and minor alloantigens on human target cells by allostimulated cytotoxic effectors in vitro. Pierson G; Elkins W Transplant Proc; 1981 Dec; 13(4):1901-5. PubMed ID: 6977223 [No Abstract] [Full Text] [Related]
14. Graft vs host disease following kidney transplantation using an '0 HLA antigen mismatched' donor. Smith DM; Agura ED; Levy MF; Melton LB; Domiati-Saad R; Klintmalm G Nephrol Dial Transplant; 2006 Sep; 21(9):2656-9. PubMed ID: 16627604 [No Abstract] [Full Text] [Related]
15. [Immunologic bases of graft vs. host disease: 1997]. Uher F Orv Hetil; 1997 Aug; 138(35):2163-8. PubMed ID: 9324676 [TBL] [Abstract][Full Text] [Related]
16. HLA 1992: typing strategies and perspectives in bone marrow transplantation. Charron DJ Transplant Proc; 1993 Feb; 25(1 Pt 1):171-2. PubMed ID: 8438262 [No Abstract] [Full Text] [Related]
17. Selection of unrelated donors for hematopoietic cell transplantation. Field T; Anasetti C Curr Hematol Rep; 2005 Jul; 4(4):270-5. PubMed ID: 16009041 [TBL] [Abstract][Full Text] [Related]